ICD Therapy Effectiveness in Non-Ischemic Heart Failure: A Meta-Analysis of 5 Trials

2573 patients were enrolled across five randomized controlled trials comparing implantable cardioverter-defibrillator (ICD) therapy plus medical treatment to medical treatment alone for non-ischemic heart failure. The meta-analysis, authored by Zhenhua Xing, derived pooled risk ratios from PubMed, Embase, and Cochrane Central databases. It found ICD therapy combined with medical treatment was associated with a significantly lower risk for all-cause mortality (Risk ratio: 0.83; 95% CI 0.71 to 0.97).

Use Cases

• Meta-analysis of treatment efficacy based on pooled risk ratios from randomized trials.
• Modeling mortality risk reduction for ICD therapy in non-ischemic heart failure patients.
• Training models to predict clinical trial outcomes based on aggregated study results.
• Systematic review support for comparing medical device interventions against standard care.

Strengths

• Analysis is based on 5 randomized controlled trials, a standard for clinical evidence.
• Includes data from 2573 total patients, providing a substantive sample size for the meta-analysis.
• Uses fixed-effects models to derive pooled risk ratios with 95% confidence intervals.

Limitations

• Row count and column-level documentation for the underlying data are unknown.
• The dataset's freshness is unverified as the last update date is unknown.
• Data may reflect publication bias inherent to systematic reviews of published trials.

Provenance

Source

paperswithcode

Collection Method

Systematic review and meta-analysis of randomized trials from PubMed, Embase, and Cochrane Central databases.